RU98111742A - 2,7-SUBSTITUTED OCTAHYDROPIROLLO 1,2-A PYRASINE DERIVATIVES - Google Patents
2,7-SUBSTITUTED OCTAHYDROPIROLLO 1,2-A PYRASINE DERIVATIVESInfo
- Publication number
- RU98111742A RU98111742A RU98111742/04A RU98111742A RU98111742A RU 98111742 A RU98111742 A RU 98111742A RU 98111742/04 A RU98111742/04 A RU 98111742/04A RU 98111742 A RU98111742 A RU 98111742A RU 98111742 A RU98111742 A RU 98111742A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- octahydropyrrolo
- pyrazine
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 20
- 239000011780 sodium chloride Substances 0.000 claims 20
- -1 benzoxazolonyl Chemical group 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004802 cyanophenyl group Chemical group 0.000 claims 6
- 125000004212 difluorophenyl group Chemical group 0.000 claims 6
- 125000001207 fluorophenyl group Chemical group 0.000 claims 6
- 229960003638 dopamine Drugs 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 206010001443 Affective disease Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000009745 Eye Disease Diseases 0.000 claims 2
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 201000001971 Huntington's disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008433 Motor Disorders Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010040984 Sleep disease Diseases 0.000 claims 2
- 206010040998 Sleep disturbance Diseases 0.000 claims 2
- 206010043118 Tardive dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 206010044126 Tourette's disease Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 230000000561 anti-psychotic Effects 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 201000006233 congestive heart failure Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000027119 gastric acid secretion Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000003211 malignant Effects 0.000 claims 2
- 201000009457 movement disease Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 231100000486 side effect Toxicity 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 201000010874 syndrome Diseases 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 201000011528 vascular disease Diseases 0.000 claims 2
- HKHFOBZOYABVDH-WDEREUQCSA-N (7R,8aS)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@H](CN1CC1)O)N1C1=CC=C(Cl)C=N1 HKHFOBZOYABVDH-WDEREUQCSA-N 0.000 claims 1
- MUNPRJATIUVQNI-VHSXEESVSA-N (7R,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@H](CN1CC1)O)N1C1=NC=C(F)C=N1 MUNPRJATIUVQNI-VHSXEESVSA-N 0.000 claims 1
- HKHFOBZOYABVDH-QWRGUYRKSA-N (7S,8aS)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@@H](CN1CC1)O)N1C1=CC=C(Cl)C=N1 HKHFOBZOYABVDH-QWRGUYRKSA-N 0.000 claims 1
- DPZQQYROVRLQBF-YOEHRIQHSA-N (7S,8aS)-2-(5-chloropyridin-2-yl)-7-[(4-fluorophenoxy)methyl]-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OC[C@@H]1CN2CCN(C=3N=CC(Cl)=CC=3)C[C@@H]2C1 DPZQQYROVRLQBF-YOEHRIQHSA-N 0.000 claims 1
- KTNLKNZYVOELFG-ROUUACIJSA-N (7S,8aS)-2-(5-chloropyridin-2-yl)-7-[(4-fluorophenyl)methoxy]-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1CO[C@@H]1CN2CCN(C=3N=CC(Cl)=CC=3)C[C@@H]2C1 KTNLKNZYVOELFG-ROUUACIJSA-N 0.000 claims 1
- MUNPRJATIUVQNI-UWVGGRQHSA-N (7S,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-ol Chemical compound C([C@@H]1C[C@@H](CN1CC1)O)N1C1=NC=C(F)C=N1 MUNPRJATIUVQNI-UWVGGRQHSA-N 0.000 claims 1
- GGGKIVRCBHWSRY-BBRMVZONSA-N (7S,8aS)-7-[(4-fluorophenoxy)methyl]-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine Chemical compound C1=CC(F)=CC=C1OC[C@@H]1CN2CCN(C=3N=CC(F)=CN=3)C[C@@H]2C1 GGGKIVRCBHWSRY-BBRMVZONSA-N 0.000 claims 1
- BDEDALBTQRDSGO-ROUUACIJSA-N 3-[[(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]oxymethyl]benzonitrile Chemical compound N1=CC(F)=CN=C1N1C[C@@H]2C[C@H](OCC=3C=C(C=CC=3)C#N)CN2CC1 BDEDALBTQRDSGO-ROUUACIJSA-N 0.000 claims 1
- SSZLEWUDHUIKLO-SQJZIBIZSA-N C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=C1 Chemical compound C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=C1 SSZLEWUDHUIKLO-SQJZIBIZSA-N 0.000 claims 1
- YOXMSGDZSNZUIB-RHGDZWTLSA-N C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=C1 Chemical compound C(#N)C1=CC=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=C1 YOXMSGDZSNZUIB-RHGDZWTLSA-N 0.000 claims 1
- JGRLEYKBYBFXAU-SQJZIBIZSA-N C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=CC=1 Chemical compound C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=C3)Cl)C2)C=CC=1 JGRLEYKBYBFXAU-SQJZIBIZSA-N 0.000 claims 1
- ZMOKVIBIPFLXIE-RHGDZWTLSA-N C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=CC=1 Chemical compound C(#N)C=1C=C(O[C@H]2C[C@@H]3N(CCN(C3C)C3=NC=C(C=N3)F)C2)C=CC=1 ZMOKVIBIPFLXIE-RHGDZWTLSA-N 0.000 claims 1
- PVYBIMHAUMUNAY-IRXDYDNUSA-N [(7S,8aS)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl] benzoate Chemical compound N1=CC(Cl)=CC=C1N1C[C@@H]2C[C@H](OC(=O)C=3C=CC=CC=3)CN2CC1 PVYBIMHAUMUNAY-IRXDYDNUSA-N 0.000 claims 1
- LHBPTLBPEMRINB-JQWIXIFHSA-N [(7S,8aS)-2-(5-chloropyridin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]methanol Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=CC=C(Cl)C=N1 LHBPTLBPEMRINB-JQWIXIFHSA-N 0.000 claims 1
- AFFHGUJDPAXTDQ-HOTGVXAUSA-N [(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl] benzoate Chemical compound N1=CC(F)=CN=C1N1C[C@@H]2C[C@H](OC(=O)C=3C=CC=CC=3)CN2CC1 AFFHGUJDPAXTDQ-HOTGVXAUSA-N 0.000 claims 1
- KREGKYQIUMOXGH-ONGXEEELSA-N [(7S,8aS)-2-(5-fluoropyrimidin-2-yl)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-7-yl]methanol Chemical compound C([C@@H]1C[C@@H](CN1CC1)CO)N1C1=NC=C(F)C=N1 KREGKYQIUMOXGH-ONGXEEELSA-N 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl N-hexyl-N-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Claims (25)
где R1 представляет фенил, нафтил, бензоксазолонил, индолил, индолонил, бензимидазолил, хинолил, фурил, бензофурил, тиенил, бензотиенил, оксазолил, бензоксазолил;
R2 представляет Н или (С1-С6)алкил;
R3 представляет фенил, пиридинил, пиримидинил, пиразинил или пиридазинил;
R4 представляет Н или (С1-С6)алкил;
R5 представляет Н или (С1-С6)алкил; где каждая группа R1 и R3 может быть независимо и необязательно замещена от одного до четырьмя заместителями, независимо выбранных из групп, включающих фтор, хлор, бром, йод, циано, нитро, тиоциано, -SR4, -SOR4, -SO2R4, -NHSO2R4, -(С1-С6)алкокси, -NR4R5, -NR4COR5, -CONR4R5, фенил, -COR4, -COOR4, -(С1-С6)алкил, -(С1-С6)алкил, замещенный от одного до шестью атомами галогена, -(С3-С6)циклоалкил и трифторметокси;
Х представляет О, S, SO, SO2, NR4, C=O, CH(OH), CHR4,
m равно 0, 1 или 2;
n равно 0, 1 или 2;
все его стереоизомеры, или его фармацевтически приемлемая соль.1. The compound of formula I
where R 1 represents phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl, quinolyl, furyl, benzofuryl, thienyl, benzothienyl, oxazolyl, benzoxazolyl;
R 2 represents H or (C 1 -C 6 ) alkyl;
R 3 represents phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl;
R 4 represents H or (C 1 -C 6 ) alkyl;
R 5 represents H or (C 1 -C 6 ) alkyl; where each group R 1 and R 3 can be independently and optionally substituted with one to four substituents independently selected from groups including fluoro, chloro, bromo, iodo, cyano, nitro, thiociano, -SR 4 , -SOR 4 , -SO 2 R 4 , -NHSO 2 R 4 , - (C 1 -C 6 ) alkoxy, -NR 4 R 5 , -NR 4 COR 5 , -CONR 4 R 5 , phenyl, -COR 4 , -COOR 4 , - ( C 1 -C 6 ) alkyl, - (C 1 -C 6 ) alkyl substituted with one to six halogen atoms, - (C 3 -C 6 ) cycloalkyl and trifluoromethoxy;
X represents O, S, SO, SO 2 , NR 4 , C = O, CH (OH), CHR 4 ,
m is 0, 1 or 2;
n is 0, 1 or 2;
all stereoisomers thereof, or a pharmaceutically acceptable salt thereof.
где R1 представляет фенил, нафтил, бензоксазолонил, индолил, индолонил, бензимидазолил или хинолил; R1 и R3 могут быть независимо замещены от одного до трех заместителями, независимо выбранными из группы, включающей фтор, хлор, бром, йод, циано, -NR4R5, -(C1-С6)алкокси, -COOR4, -CONR4R5, -(С1-С6)алкил, -(С1-С6)алкил, замещенный от одного до шестью галогенами, -(С3-С6)циклоалкил и трифторметокси;
R2 представляет Н или СН3;
Х представляет О, С=O, СН=ОН, -С(=O)O- или СН2;
m равно 0 или 1;
n равно 0 или 1;
или его фармацевтически приемлемая соль.2. The compound of claim 1,
where R 1 represents phenyl, naphthyl, benzoxazolonyl, indolyl, indolonyl, benzimidazolyl or quinolyl; R 1 and R 3 can be independently substituted by one to three substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, —NR 4 R 5 , - (C 1 –C 6 ) alkoxy, —COOR 4 , -CONR 4 R 5 , - (C 1 -C 6 ) alkyl, - (C 1 -C 6 ) alkyl substituted with one to six halogens, - (C 3 -C 6 ) cycloalkyl and trifluoromethoxy;
R 2 represents H or CH 3 ;
X represents O, C = O, CH = OH, —C (= O) O— or CH 2 ;
m is 0 or 1;
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фенил или замещенный фенил,
R3 представляет замещенный или незамещенный фенил, пиридинил или пиримидинил;
X представляет O, -C(=O)O- или CH2;
или его фармацевтически приемлемая соль.3. The compound according to claim 2,
where R 1 represents phenyl or substituted phenyl,
R 3 represents substituted or unsubstituted phenyl, pyridinyl or pyrimidinyl;
X represents O, —C (═O) O— or CH 2 ;
or a pharmaceutically acceptable salt thereof.
R2 представляет Н;
Х представляет О;
m равно 0;
n равно 1.4. The compound according to claim 3, where
R 2 represents H;
X represents O;
m is 0;
n is 1.
где R2 представляет Н;
Х представляет О;
m равно 1;
n равно 0;
или его фармацевтически приемлемая соль.5. The compound according to claim 3,
where R 2 represents H;
X represents O;
m is 1;
n is 0;
or a pharmaceutically acceptable salt thereof.
где R2 представляет Н;
Х представляет -С(=O)O-;
m равно 0;
n равно 0;
или его фармацевтически приемлемая соль.6. The compound according to claim 3,
where R 2 represents H;
X represents —C (═O) O—;
m is 0;
n is 0;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет хлорпиридинил;
или его фармацевтически приемлемая соль.7. The compound according to claim 4,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 is chloropyridinyl;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет фторпиримидинил;
или его фармацевтически приемлемая соль.8. The compound according to claim 4,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 represents fluoropyrimidinyl;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет хлорпиридинил;
или его фармацевтически приемлемая соль.9. The compound according to claim 5,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 is chloropyridinyl;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет фторпиримидинил;
или его фармацевтически приемлемая соль.10. The compound according to claim 5,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 represents fluoropyrimidinyl;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет хлорпиридинил;
или его фармацевтически приемлемая соль.11. The compound according to claim 6,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 is chloropyridinyl;
or a pharmaceutically acceptable salt thereof.
где R1 представляет фторфенил, дифторфенил или цианофенил;
R3 представляет фторпиримидинил;
или его фармацевтически приемлемая соль.12. The compound according to claim 6,
where R 1 represents fluorophenyl, difluorophenyl or cyanophenyl;
R 3 represents fluoropyrimidinyl;
or a pharmaceutically acceptable salt thereof.
(7S,8аS)-7-(4-фторфенокси)метил-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8aS)-7-(3,5-дифторфенокси)метил-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-7-(3-цианофенокси)метил-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-7-(4-цианофенокси)метил-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S, 8аS)-7-(4-фторбензил)окси-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а] пиразин-7-ил бензоат;
(7S,8аS)-7-(4-фторфенокси)метил-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8aS)-7-(3,5-дифторфенокси)метил-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-7-(3-цианофенокси)метил-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-7-(4-цианофенокси)метил-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S,8аS)-7-(4-фторбенэил)окси-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S, 8аS)-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин-7-ил бензоат;
(7S,8аS)-7-(3-цианобензил)окси-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин.19. The compound according to claim 1, which is selected from the group including:
(7S, 8aS) -7- (4-fluorophenoxy) methyl-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (3,5-difluorophenoxy) methyl-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2 a] pyrazine;
(7S, 8aS) -7- (3-cyanophenoxy) methyl-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (4-cyanophenoxy) methyl-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (4-fluorobenzyl) oxy-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazin-7-yl benzoate;
(7S, 8aS) -7- (4-fluorophenoxy) methyl-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (3,5-difluorophenoxy) methyl-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2 a] pyrazine;
(7S, 8aS) -7- (3-cyanophenoxy) methyl-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (4-cyanophenoxy) methyl-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -7- (4-fluorobeneyl) oxy-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine;
(7S, 8aS) -2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazin-7-yl benzoate;
(7S, 8aS) -7- (3-cyanobenzyl) oxy-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a ] pyrazine.
где n равно 0 или 1;
Y представляет СН или N;
Z представляет хлор или фтор;
все его стереоизомеры.24. The compound of formula IV
where n is 0 or 1;
Y represents CH or N;
Z represents chlorine or fluorine;
all its stereoisomers.
(7S, 8аS)-7-гидроксиметил-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S, 8аS)-7-гидроксиметил-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7R, 8аS)-7-гидрокси-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7R, 8аS)-7-гидрокси-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7S, 8аS)-7-гидрокси-2-(5-хлорпиридин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин;
(7s, 8аs)-7-гидрокси-2-(5-фторпиримидин-2-ил)-1,2,3,4,6,7,8,8а-октагидропирроло[1,2-а]пиразин.25. The compound according to paragraph 24, selected from the group including:
(7S, 8aS) -7-hydroxymethyl-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine;
(7S, 8aS) -7-hydroxymethyl-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine;
(7R, 8aS) -7-hydroxy-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine;
(7R, 8aS) -7-hydroxy-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine;
(7S, 8aS) -7-hydroxy-2- (5-chloropyridin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine;
(7s, 8as) -7-hydroxy-2- (5-fluoropyrimidin-2-yl) -1,2,3,4,6,7,8,8a-octahydropyrrolo [1,2-a] pyrazine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US898895P | 1995-12-21 | 1995-12-21 | |
US60/008,988 | 1995-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98111742A true RU98111742A (en) | 2000-03-27 |
RU2162470C2 RU2162470C2 (en) | 2001-01-27 |
Family
ID=21734893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98111742/04A RU2162470C2 (en) | 1995-12-21 | 1996-11-06 | 2,7-substituted derivatives of octahydropyrrolo[1,2-a]pyrazine, method of treatment, pharmaceutical composition, and intermediates |
Country Status (33)
Country | Link |
---|---|
US (1) | US5714487A (en) |
EP (1) | EP0874849B1 (en) |
JP (1) | JP3204456B2 (en) |
KR (1) | KR100286786B1 (en) |
CN (1) | CN1061350C (en) |
AR (1) | AR005102A1 (en) |
AT (1) | ATE205846T1 (en) |
AU (1) | AU704578B2 (en) |
BR (1) | BR9612246A (en) |
CA (1) | CA2240594C (en) |
CO (1) | CO4480107A1 (en) |
CZ (1) | CZ192998A3 (en) |
DE (1) | DE69615404T2 (en) |
DK (1) | DK0874849T3 (en) |
ES (1) | ES2161377T3 (en) |
GR (1) | GR3037060T3 (en) |
GT (1) | GT199600101A (en) |
HU (1) | HUP9900611A3 (en) |
IL (1) | IL124453A0 (en) |
MA (1) | MA26413A1 (en) |
MX (1) | MX9805088A (en) |
NO (1) | NO309936B1 (en) |
NZ (1) | NZ320537A (en) |
PE (1) | PE25998A1 (en) |
PL (1) | PL327539A1 (en) |
PT (1) | PT874849E (en) |
RU (1) | RU2162470C2 (en) |
SI (1) | SI0874849T1 (en) |
TN (1) | TNSN96164A1 (en) |
TR (1) | TR199801161T2 (en) |
TW (1) | TW479058B (en) |
WO (1) | WO1997023482A1 (en) |
ZA (1) | ZA9610781B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281216B1 (en) * | 1998-02-09 | 2001-08-28 | Duphar International Research B.V. | 2-aminoquinoline derivatives having d4-agonistic activity |
EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
CA2358865A1 (en) * | 1999-02-05 | 2000-08-10 | Pharmacia & Upjohn Company | Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one |
US7091199B1 (en) | 1999-09-14 | 2006-08-15 | Aventis Pharmaceuticals Inc. | Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists |
US7125903B1 (en) | 1999-09-14 | 2006-10-24 | Aventis Pharmaceuticals Inc. | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
NZ517516A (en) * | 1999-09-14 | 2003-11-28 | Aventis Pharma Inc | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl- phenoxy derivatives useful as D4 antagonists |
US7253165B2 (en) | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
TW200801005A (en) * | 2005-08-15 | 2008-01-01 | Astrazeneca Ab | Acetylenic piperazines as metabotropic glutamate receptor antagonists |
US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
KR102639990B1 (en) * | 2018-03-28 | 2024-02-27 | 신토고교 가부시키가이샤 | Electric lift device and roll press device with electric lift device |
JP7460264B2 (en) * | 2018-09-04 | 2024-04-02 | コンティニューム・セラピューティクス・インコーポレイテッド | Muscarinic acetylcholine M1 receptor antagonists |
US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4400511A (en) * | 1982-05-07 | 1983-08-23 | American Home Products Corporation | 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids |
MX19222A (en) * | 1989-01-23 | 1993-12-01 | Pfizer | ANSIOLYTIC AGENTS BIS-AZA-BICYCLIC |
US5122515A (en) * | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
JP3058945B2 (en) * | 1990-10-26 | 2000-07-04 | 三共株式会社 | N- (3,3-disubstituted acryloyl) piperazine derivatives |
JPH08502508A (en) * | 1992-10-23 | 1996-03-19 | メルク シヤープ エンド ドーム リミテツド | Dopamine receptor subtype ligand |
WO1994010162A1 (en) * | 1992-10-23 | 1994-05-11 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
DK0775118T3 (en) * | 1994-08-05 | 2003-09-29 | Pfizer | Benzimidazole derivatives having dopaminergic activity |
KR100244848B1 (en) * | 1994-09-30 | 2000-03-02 | 디. 제이. 우드, 스피겔 알렌 제이 | 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
-
1996
- 1996-11-06 WO PCT/IB1996/001192 patent/WO1997023482A1/en not_active Application Discontinuation
- 1996-11-06 ES ES96935226T patent/ES2161377T3/en not_active Expired - Lifetime
- 1996-11-06 PT PT96935226T patent/PT874849E/en unknown
- 1996-11-06 PL PL96327539A patent/PL327539A1/en unknown
- 1996-11-06 HU HU9900611A patent/HUP9900611A3/en unknown
- 1996-11-06 CA CA002240594A patent/CA2240594C/en not_active Expired - Fee Related
- 1996-11-06 DK DK96935226T patent/DK0874849T3/en active
- 1996-11-06 DE DE69615404T patent/DE69615404T2/en not_active Expired - Fee Related
- 1996-11-06 AU AU73280/96A patent/AU704578B2/en not_active Ceased
- 1996-11-06 SI SI9630343T patent/SI0874849T1/xx unknown
- 1996-11-06 CZ CZ981929A patent/CZ192998A3/en unknown
- 1996-11-06 AT AT96935226T patent/ATE205846T1/en not_active IP Right Cessation
- 1996-11-06 CN CN96199250A patent/CN1061350C/en not_active Expired - Fee Related
- 1996-11-06 EP EP96935226A patent/EP0874849B1/en not_active Expired - Lifetime
- 1996-11-06 JP JP52344697A patent/JP3204456B2/en not_active Expired - Fee Related
- 1996-11-06 IL IL12445396A patent/IL124453A0/en unknown
- 1996-11-06 BR BR9612246A patent/BR9612246A/en not_active Application Discontinuation
- 1996-11-06 TR TR1998/01161T patent/TR199801161T2/en unknown
- 1996-11-06 RU RU98111742/04A patent/RU2162470C2/en not_active IP Right Cessation
- 1996-11-06 NZ NZ320537A patent/NZ320537A/en unknown
- 1996-11-06 KR KR1019980704718A patent/KR100286786B1/en not_active IP Right Cessation
- 1996-11-08 TW TW085113669A patent/TW479058B/en not_active IP Right Cessation
- 1996-12-16 AR ARP960105715A patent/AR005102A1/en not_active Application Discontinuation
- 1996-12-16 PE PE1996000913A patent/PE25998A1/en not_active Application Discontinuation
- 1996-12-18 TN TNTNSN96164A patent/TNSN96164A1/en unknown
- 1996-12-18 MA MA24432A patent/MA26413A1/en unknown
- 1996-12-19 GT GT199600101A patent/GT199600101A/en unknown
- 1996-12-20 CO CO96066997A patent/CO4480107A1/en unknown
- 1996-12-20 ZA ZA9610781A patent/ZA9610781B/en unknown
- 1996-12-23 US US08/774,290 patent/US5714487A/en not_active Expired - Fee Related
-
1998
- 1998-06-19 NO NO982843A patent/NO309936B1/en unknown
- 1998-06-22 MX MX9805088A patent/MX9805088A/en unknown
-
2001
- 2001-10-30 GR GR20010401932T patent/GR3037060T3/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98111742A (en) | 2,7-SUBSTITUTED OCTAHYDROPIROLLO 1,2-A PYRASINE DERIVATIVES | |
KR940005566A (en) | Quinoline compounds | |
RU2219178C2 (en) | Bicyclic derivatives, pharmaceutical composition based on thereof and intermediate compounds | |
CN105837584B (en) | The imidazole radicals imidazoles of condensation as antiviral compound | |
CA2602294C (en) | Heterobicylic inhibitors of hvc | |
US6432989B1 (en) | Use of CRF antagonists to treat circadian rhythm disorders | |
CN102816175A (en) | Heterocyclic and pyridone type compound, intermediate, preparation method and application thereof | |
KR20190080897A (en) | Substituted pyridinone-containing tricyclic compounds, and methods of use thereof | |
CA2448306A1 (en) | Method for treating fibrotic diseases or other indications | |
CN108366992A (en) | Proteolysis targets chimera compound and its methods for making and using same | |
ZA200606636B (en) | Therapeutic combinations of atypical antipsychotic with corticotropin releasing factor antagonists | |
AU2263400A (en) | QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death | |
RU2007116850A (en) | THROMBIN RECEPTOR ANTAGONISTS | |
JP2004525149A5 (en) | ||
JP2006514003A5 (en) | ||
CN104487442A (en) | Antiviral compounds inhibitors of HCV NS5B | |
JP2005507878A5 (en) | ||
RU2002131887A (en) | AMRIDES OF ANTANILIC ACID SUBSTITUTED IN THE ORTHO SITUATION AND THEIR APPLICATION AS MEDICINES | |
JP2012501327A5 (en) | ||
RU2005136370A (en) | TRICYCLIC INDOLE DERIVATIVES AND THEIR APPLICATION IN TREATMENT OF ALZHEIMER'S DISEASE | |
JP2008510712A5 (en) | ||
KR20150129729A (en) | Compounds for treatment of fibrosis diseases | |
WO2010126082A1 (en) | Therapeutic agent for motor disorders | |
JP2016501883A5 (en) | ||
RU97105362A (en) | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO [1,2-A] PYRASINE DERIVATIVES |